BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012;130:2685-92. [PMID: 21780114 DOI: 10.1002/ijc.26301] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954. [PMID: 30412113 DOI: 10.1097/MD.0000000000012954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:117. [PMID: 24559042 DOI: 10.1186/1471-207-14-117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zheng SS, Chen XH, Yin X, Zhang BH. Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e65753. [PMID: 23799043 DOI: 10.1371/journal.pone.0065753] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
4 Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat Mon 2015;15:e30753. [PMID: 26500684 DOI: 10.5812/hepatmon.30753] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
5 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gao JZ, Li J, DU JL, Li XL. Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence. Oncol Lett. 2016;11:1791-1798. [PMID: 26998078 DOI: 10.3892/ol.2016.4130] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 10.5] [Reference Citation Analysis]
7 Xiao WK, Qi CY, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:104. [PMID: 24548704 DOI: 10.1186/1471-2407-14-104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
8 da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer. 2015;136:172-181. [PMID: 24803312 DOI: 10.1002/ijc.28953] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
9 Xue TC, Zhang L, Xie XY, Ge NL, Li LX, Zhang BH, Ye SL, Ren ZG. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS One 2014;9:e96072. [PMID: 24788770 DOI: 10.1371/journal.pone.0096072] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
10 Yilmaz Y, Ozturk O, Alahdab YO, Senates E, Colak Y, Doganay HL, Coskunpinar E, Oltulu YM, Eren F, Atug O, Tuncer I, Imeryuz N. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis 2013;45:58-62. [PMID: 22995553 DOI: 10.1016/j.dld.2012.08.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
11 Zhang S, Chen S, Yang G, Gu F, Li M, Zhong B, Hu J, Hoffman A, Chen M. Long noncoding RNA HOTAIR as an independent prognostic marker in cancer: a meta-analysis. PLoS One 2014;9:e105538. [PMID: 25157956 DOI: 10.1371/journal.pone.0105538] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
12 Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, Olsen A, Tjønneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Quirós JR, Agudo A, Sánchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) 2016;9:758-65. [PMID: 27339170 DOI: 10.1158/1940-6207.CAPR-15-0434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
13 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
14 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
15 Srungaram P, Rule JA, Yuan HJ, Reimold A, Dahl B, Sanders C, Lee WM. Plasma osteopontin in acute liver failure. Cytokine. 2015;73:270-276. [PMID: 25802196 DOI: 10.1016/j.cyto.2015.02.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
16 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
17 Linhares MM, Affonso RJ Jr, Viana Lde S, Silva SR, Denadai MV, de Toledo SR, Matos D. Genetic and Immunohistochemical Expression of Integrins ITGAV, ITGA6, and ITGA3 As Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival. PLoS One 2015;10:e0144333. [PMID: 26674523 DOI: 10.1371/journal.pone.0144333] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
18 Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore) 2018;97:e11130. [PMID: 29901640 DOI: 10.1097/MD.0000000000011130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
19 Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One. 2016;11:e0151069. [PMID: 26986465 DOI: 10.1371/journal.pone.0151069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
20 Liu Y, Tang W, Xie L, Wang J, Deng Y, Peng Q, Zhai L, Li S, Qin X. Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis. Tumour Biol. 2014;35:3145-3154. [PMID: 24258111 DOI: 10.1007/s13277-013-1411-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
21 Salem M, Atti SA, Raziky ME, Darweesh SK, Sharkawy ME. Clinical Significance of Plasma Osteopontin Level as a Biomarker of Hepatocellular Carcinoma. Gastroenterology Res 2013;6:191-9. [PMID: 27785253 DOI: 10.4021/gr499w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
22 Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 2013;58:1992-2000. [PMID: 23775819 DOI: 10.1002/hep.26577] [Cited by in Crossref: 77] [Cited by in F6Publishing: 125] [Article Influence: 8.6] [Reference Citation Analysis]
23 Khalil A, Elgedawy J, Faramawi MF, Elfert A, Salama I, Abbass A, Elsaid H, Elsebaai H. Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions. Tumori 2013;99:100-7. [DOI: 10.1177/030089161309900117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
24 Huang X, Qian Y, Wu H, Xie X, Zhou Q, Wang Y, Kuang W, Shen L, Li K, Su J, Shen L, Chen X. Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma. J Histochem Cytochem 2015;63:88-98. [PMID: 25380749 DOI: 10.1369/0022155414561329] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
25 Jin Y, Chen JN, Feng ZY, Zhang ZG, Fan WZ, Wang Y, Li JP. OPN and αvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma. PLoS One. 2014;9:e87930. [PMID: 24498405 DOI: 10.1371/journal.pone.0087930] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
26 Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:117. [PMID: 24559042 DOI: 10.1186/1471-2407-14-117] [Cited by in Crossref: 127] [Cited by in F6Publishing: 132] [Article Influence: 15.9] [Reference Citation Analysis]
27 Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44:22-30. [PMID: 23701387 DOI: 10.1111/hepr.12166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
28 Wu Y, Jiang W, Wang Y, Wu J, Saiyin H, Qiao X, Mei X, Guo B, Fang X, Zhang L, Lou H, Wu C, Qiao S. Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS One 2012;7:e42976. [PMID: 22927944 DOI: 10.1371/journal.pone.0042976] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]